Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04120415
Other study ID # EHVA T02/ANRS VRI07
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 21, 2022
Est. completion date July 12, 2023

Study information

Verified date July 2023
Source ANRS, Emerging Infectious Diseases
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

EHVA T02 is an international, phase II, double-blind study to evaluate two experimental arms each compared to placebo control in HIV-1 positive participants to see if either has a clinically relevant impact on viral replication.


Description:

Screening will take place during the 6 weeks prior to randomisation. Eligible participants will be enrolled at week 0 and randomised to MVA HIV-B vaccine followed by vedolizumab, vedolizumab + placebo vaccine, or placebo vaccine + placebo infusions. Participants will be randomised at each centre through web-based randomisation after entering the eligibility criteria. There will be two strata: one for those who started treatment during primary infection, and one for those who started treatment during chronic infection. 69 eligible individuals from collaborating European Countries will be enrolled, aiming for approximately half who started cART in primary infection and half who started in chronic infection. Participants continue from the screening visit (up to 6 weeks before enrolment) to the last visit, a maximum of 60 weeks (around 14 months), although follow-up will continue through to the time when virus is fully suppressed. Treatment will be interrupted at week 18 and resumed when the viral load is confirmed to have rebounded to ≥100,000 copies/ml, or the CD4 falls to ≤350 cells/mm3, confirmed, or there is evidence of disease progression, or they have completed 24 weeks of treatment interruption.


Recruitment information / eligibility

Status Completed
Enrollment 2
Est. completion date July 12, 2023
Est. primary completion date July 12, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. HIV-1-infected 2. Aged 18 - 65 years old on the day of screening 3. Weight >50kg 4. Willing and able to provide written informed consent 5. Nadir CD4 count > 300 cells/mm3 6. CD4 count at screening > 500 cells/mm3 7. Viral load <50 copies/ml at screening. 8. Started cART after 2009 and on cART for at least one year prior to screening 9. Willing to interrupt cART for up to 24 weeks and change cART regimen if required 10. If sexually active, willing to use a reliable method of reducing the risk of transmission to their sexual partners during treatment interruption (which could include PrEP for their sexual partners) 11. If heterosexually active and able to have children, willing to use a highly effective method of contraception with partner (combined oral contraceptive pill; injectable or implanted contraceptive; IUD/IUS; physiological or anatomical sterility (in self or partner) from 2 weeks before enrolment until 18 weeks after the last injection/infusion 12. If women of childbearing potential*, willing to undergo urine pregnancy tests prior to administration of an injection and an infusion 13. Willing to avoid all other vaccines within 4 weeks of scheduled study injections 14. Willing and able to comply with visit schedule and provide blood samples 15. Being covered by medical insurance or in National Healthcare System - A woman will be considered of childbearing potential following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Exclusion Criteria: 1. Pregnant or lactating 2. HIV-2 infection (either isolated or associated with HIV-1) 3. VL >200 copies/ml on 2 occasions in the 12 months prior to screening 4. Previous interruptions in cART 5. Previous virological failures defined by loss of virological suppression with the presence of resistant mutations 6. Haemoglobin (Hb <12g/dL for males, <11g/dL for females) 7. Concomitant or previous conditions that preclude injection of vaccines/infusion of monoclonal antibody and PML in the past 8. History of experimental vaccinations against HIV 9. Previous treatment with chemotherapy (except for chemotherapy injected into skin lesions for Kaposi's sarcoma) 10. Treatment with systemic corticoids or immuno-suppressive agents ongoing or in the 12 weeks prior to randomisation in the trial 11. Received natalizumab or rituximab ever in the past 12. Received a TNF blocker in the past 60 days 13. Administration of an inactivated vaccine within 30 days or a live vaccine within 60 days prior to randomisation 14. Presence of a skin condition or marking that precludes inspection of the injection/infusion site 15. History of cancer (except basal cellular skin carcinoma or Kaposi's sarcoma) 16. History of significant neurological disease or cardiovascular disease (angina, myocardial infarction, transient ischemic attack, stroke); participants with controlled blood pressure are eligible 17. History of clinical autoimmune disease 18. Ongoing diseases including uncontrolled active severe infection, cardiac, pulmonary (excluding mild asthma), thyroid, renal or neurological (peripheral or central) diseases 19. Active or latent tuberculosis (unless prophylaxis in past as per local practice) - (participant must be screened for tuberculosis before starting infusions, according to routine practice) 20. Presence of pathogenic bacteria or parasites in faeces at screening 21. Participating in another biomedical research study within 30 days of randomisation 22. Known hypersensitivity to any component of the vaccine formulation used in this trial including eggs or have severe or multiple allergies to drugs or pharmaceutical agents, or any hypersensitivity to the active substance or to any of the excipients of vedolizumab. 23. Liver disease including hepatitis B (surface antigen positive) or hepatitis C (antigen or PCR positive) 24. A clinically significant abnormality on ECG 25. Hypernatraemia or hyperchloraemia 26. History of severe local or general reaction to vaccination defined as 1. local: extensive, indurated redness and swelling involving most of the arm, not resolving within 72 hours 2. general: fever >= 39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours 27. Grade 2 or worse routine laboratory parameters. Hyperbilirubinaemia to be considered an exclusion criterion only when confirmed to be conjugated bilirubinaemia

Study Design


Intervention

Biological:
Vaccine and vedolizumab (Entyvio)
Vaccine and vedolizumab infusion (Entyvio): 0.5ml of MVA HIV-B (1 x 108 pfu/ml) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection. Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion.
Placebo vaccine and vedolizumab infusion (Entyvio)
Placebo Vaccine: The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection. Vedolizumab infusion (Entyvio): Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion.
Placebo vaccine and placebo infusion
Placebo Vaccine: The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection. Placebo infusion (Entyvio): 255ml Sodium Chloride (NaCl) 0.9% bag administered as an intravenous infusion over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. Participants will be observed throughout and after the infusion.

Locations

Country Name City State
France Hotel Dieu Paris
France Service Immunologie clinique et maladies infectieuses, Hôpital Henri Mondor Paris Creteil
Switzerland Centre d'Immunothérapie et Vaccinologie, CHUV Lausanne Vaud
United Kingdom St Stephens Centre, Chelsea & Westminster Hospital London

Sponsors (19)

Lead Sponsor Collaborator
ANRS, Emerging Infectious Diseases Centre Hospitalier Universitaire Vaudois, Chelsea and Westminster Hospital, UK, Erasmus Medical Center, European AIDS Treatment Group (EATG), European Commission, European Georges Pompidou Hospital, EuroVacc Foundation, Henri Mondor University Hospital, Hospital Clinic of Barcelona, Imperial College London, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Istituto Nazionale Malattie Infettive Lazaro Spallanzani, Medical Research Council, Saint-Louis Hospital, Paris, France, Swiss Government, Universitätsklinikum Hamburg-Eppendorf, University College London Hospitals, University of Liverpool

Countries where clinical trial is conducted

France,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Safety outcome measures: Grade 3 or worse solicited clinical and laboratory adverse events Occurrence of grade 3 or worse solicited clinical and laboratory adverse events From randomisation to study completion about 54 weeks
Other Safety outcome measures: Any adverse event leading to interruption in the vaccine/placebo or vedolizumab/placebo Occurrence of any adverse event leading to interruption in the vaccine/placebo or vedolizumab/placebo From randomisation to study completion about 54 weeks
Other Safety outcome measures: Any event that results in resuming treatment during the ATI Occurrence of any event that results in resuming treatment during the ATI Time form treatment interruption to resuming treatment, up to 24 weeks after ATI
Other Safety outcome measures: Serious Adverse Events Occurrence of Serious Adverse Events From randomisation until 30 days after the last protocol visit
Other Safety outcome measures: Other clinical and laboratory adverse events Occurrence of other clinical and laboratory adverse events From randomisation to study completion about 54 weeks
Other Safety outcome measures: Change in absolute CD4 Observation of change in absolute CD4 count From randomisation to study completion about 54 weeks
Other Safety outcome measures: Time to VL suppression after restarting cART Time to VL suppression after restarting cART From randomisation to VL suppression (= VL is undetectable (<50copies/ml)) after restarting cART until the participant returns to an undetectable viral load, about 54 weeks]
Other Exploratory Immunological outcome measures: Characterization of vaccine induced CD4 and CD8 T-cell produced cytokine profile Observation of vaccine induced CD4 and CD8 T-cell produced cytokines by flow cytometry From randomisation to study completion about 54 weeks
Primary Area under the HIV RNA curve Area under the HIV RNA curve from treatment interruption (scheduled for 18 weeks after entering the trial) Time from treatment interruption (scheduled for 18 weeks after entering the trial) to 24 weeks post-treatment interruption
Secondary Virological outcome measures Time from treatment interruption (scheduled for 18 weeks after entering the trial) to the earliest of reaching HIV RNA = 100 000 copies/ml (confirmed on a separate sample) or resuming antiretroviral therapy for any reason over a period of 24 weeks. For participants commencing treatment interruption only, critical time points weeks 19 through to to week 42.
Secondary Virological outcome measures Level of HIV total RNA From randomisation to study completion about 54 weeks
Secondary Virological outcome measures Cell Associated (CA) HIV RNA Quantification From randomisation to study completion about 54 weeks
Secondary Virological outcome measures First local maximum (peak) level of HIV total RNA during treatment interruption Time from treatment interruption, only in participants commencing treatment interruption, up to 24 weeks after ATI
Secondary Virological outcome measures Rate of increase of HIV total RNA between the last measure below the lower detection and the first local maximum Time from treatment interruption, only in participants commencing treatment interruption, up to 24 weeks after ATI
Secondary Virological outcome measures Setpoint (two stable measures following a transient increase of HIV RNA) Time from treatment interruption, only in participants commencing treatment interruption, up to 24 weeks after ATI
See also
  Status Clinical Trial Phase
Recruiting NCT03940521 - Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
Completed NCT03227731 - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women Phase 2/Phase 3
Completed NCT03570918 - MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy Phase 1
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Active, not recruiting NCT04022967 - ANRS 12372 MODERATO Study Phase 3
Not yet recruiting NCT06337032 - A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments Phase 4
Not yet recruiting NCT06282783 - Studying Topiramate for Re-Activating the HIV-1 Reservoir Phase 1/Phase 2
Completed NCT04711265 - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Recruiting NCT03536234 - Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients Phase 2
Completed NCT04340388 - Contribution of Dolutegravir to Obesity and Cardiovascular Disease Phase 4
Withdrawn NCT05769569 - Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission Phase 1
Enrolling by invitation NCT05584397 - Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
Completed NCT04963712 - Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder Early Phase 1
Not yet recruiting NCT04894357 - Impact of V106I on Resistance to Doravirine
Completed NCT04388904 - Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART) Phase 4
Completed NCT04568239 - Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
Not yet recruiting NCT04513496 - Telemedicine in HIV Care in Buenos Aires
Not yet recruiting NCT04311957 - Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults Phase 4
Not yet recruiting NCT04311944 - Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD N/A
Completed NCT03998176 - Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE Phase 4